Exelixis Newsroom

Exelixis Is Maintained at Overweight by Piper Sandler

Dow JonesJan 13 10:33 ET

BofA Securities Maintains Exelixis(EXEL.US) With Hold Rating, Maintains Target Price $39

Moomoo NewsJan 13 10:33 ET

Exelixis Analyst Ratings

BenzingaJan 13 10:24 ET

Exelixis (EXEL) Receives a Hold From Bank of America Securities

TipRanksJan 13 09:51 ET

Piper Sandler Maintains Exelixis(EXEL.US) With Buy Rating, Raises Target Price to $37

Moomoo NewsJan 13 08:31 ET

TD Cowen Keeps Their Buy Rating on Exelixis (EXEL)

TipRanksJan 13 07:49 ET

Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Vertex Pharmaceuticals (VRTX)

TipRanksJan 13 06:51 ET

Citi Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $38

Moomoo NewsJan 13 06:31 ET

Exelixis: Hold Rating Amid Stable Performance and Moderate Growth Expectations

TipRanksJan 12 20:28 ET

Exelixis Analyst Ratings

BenzingaJan 10 08:19 ET

H.C. Wainwright Maintains Exelixis(EXEL.US) With Buy Rating, Raises Target Price to $40

Moomoo NewsJan 10 06:31 ET

RBC Capital Remains a Buy on Exelixis (EXEL)

TipRanksJan 9 20:56 ET

Citi Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $38

Moomoo NewsJan 9 12:31 ET

Positive FDA Signal and Growth Prospects Drive Buy Rating for Exelixis

TipRanksJan 9 12:07 ET

Exelixis Analyst Ratings

BenzingaJan 7 11:52 ET

Guggenheim Maintains Buy on Exelixis, Raises Price Target to $42

BenzingaJan 7 11:52 ET

Guggenheim Maintains Exelixis(EXEL.US) With Buy Rating, Raises Target Price to $42

Moomoo NewsJan 7 08:31 ET

RBC Capital Maintains Exelixis(EXEL.US) With Buy Rating, Raises Target Price to $38

Moomoo NewsDec 30, 2024 06:32 ET

Brookline Capital Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $40

Moomoo NewsDec 26, 2024 10:32 ET

Brookline Capital Initiates Exelixis(EXEL.US) With Buy Rating, Announces Target Price $40

Moomoo NewsDec 23, 2024 05:34 ET